Q2 2024 EPS Estimates for Viking Therapeutics, Inc. (NASDAQ:VKTX) Cut by HC Wainwright

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities research analysts at HC Wainwright cut their Q2 2024 earnings per share (EPS) estimates for Viking Therapeutics in a research report issued to clients and investors on Thursday, April 25th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of ($0.28) for the quarter, down from their previous estimate of ($0.19). HC Wainwright has a “Buy” rating and a $90.00 price objective on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q3 2024 earnings at ($0.29) EPS, Q4 2024 earnings at ($0.30) EPS and FY2024 earnings at ($1.14) EPS.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Wednesday, April 24th. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. During the same period last year, the firm posted ($0.25) EPS.

A number of other research firms have also recently commented on VKTX. Stifel Nicolaus restated a “buy” rating and set a $80.00 target price on shares of Viking Therapeutics in a research report on Friday, March 15th. Jefferies Financial Group initiated coverage on Viking Therapeutics in a research report on Thursday, March 7th. They issued a “buy” rating and a $110.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a research report on Friday, February 23rd. Raymond James boosted their price target on shares of Viking Therapeutics from $37.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, February 27th. Finally, Maxim Group reaffirmed a “buy” rating and set a $120.00 price objective on shares of Viking Therapeutics in a report on Friday, March 15th. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $112.25.

Viking Therapeutics Trading Up 5.5 %

Viking Therapeutics stock opened at $79.58 on Monday. The firm has a market cap of $8.78 billion, a PE ratio of -85.57 and a beta of 1.05. The stock’s 50 day simple moving average is $69.90 and its two-hundred day simple moving average is $36.01. Viking Therapeutics has a 12 month low of $8.28 and a 12 month high of $99.41.

Insider Buying and Selling

In other Viking Therapeutics news, Director Sarah Kathryn Rouan sold 25,000 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $28.05, for a total value of $701,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Viking Therapeutics news, Director Sarah Kathryn Rouan sold 25,000 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $28.05, for a total value of $701,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Brian Lian sold 269,079 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $26.87, for a total transaction of $7,230,152.73. Following the transaction, the chief executive officer now directly owns 2,184,882 shares in the company, valued at approximately $58,707,779.34. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by company insiders.

Institutional Trading of Viking Therapeutics

Several hedge funds have recently made changes to their positions in the company. Private Advisor Group LLC acquired a new position in Viking Therapeutics in the first quarter valued at approximately $369,000. North Star Investment Management Corp. acquired a new position in shares of Viking Therapeutics in the 1st quarter valued at $148,000. Caprock Group LLC purchased a new position in shares of Viking Therapeutics during the 1st quarter worth $542,000. Commonwealth Equity Services LLC acquired a new stake in shares of Viking Therapeutics during the 1st quarter worth about $1,422,000. Finally, Principal Financial Group Inc. raised its holdings in Viking Therapeutics by 3,146.7% in the 1st quarter. Principal Financial Group Inc. now owns 360,839 shares of the biotechnology company’s stock valued at $29,589,000 after buying an additional 349,725 shares during the period. Hedge funds and other institutional investors own 76.03% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.